Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Pharmacogenomics Knowledge for Personalized Medicine
20121.3k citationsMichelle Whirl‐Carrillo, Ellen M. McDonagh et al.Clinical Pharmacology & Therapeuticsprofile →
Doxorubicin pathways
20101.3k citationsCaroline F. Thorn, Howard L. McLeod et al.Pharmacogenetics and Genomicsprofile →
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
2011772 citationsTeri E. Klein et al.Clinical Pharmacology & Therapeuticsprofile →
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013680 citationsStuart A. Scott, Katrin Sangkuhl et al.Clinical Pharmacology & Therapeuticsprofile →
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
2014453 citationsAndrea Gaedigk, Henry M. Dunnenberger et al.Clinical Pharmacology & Therapeuticsprofile →
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update
2016450 citationsKatrin Sangkuhl, Andrea Gaedigk et al.Clinical Pharmacology & Therapeuticsprofile →
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
2017406 citationsUrsula Amstutz, Linda M. Henricks et al.Clinical Pharmacology & Therapeuticsprofile →
Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update
2018403 citationsMary V. Relling, Matthias Schwab et al.Clinical Pharmacology & Therapeuticsprofile →
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
2011401 citationsMary V. Relling, Sook Wah Yee et al.Clinical Pharmacology & Therapeuticsprofile →
Metformin pathways
2012380 citationsLi Gong, Russ B. Altman et al.Pharmacogenetics and Genomicsprofile →
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
2019369 citationsKelly E. Caudle, Katrin Sangkuhl et al.profile →
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
2016354 citationsKelly E. Caudle, Henry M. Dunnenberger et al.profile →
Prediction of CYP2D6 phenotype from genotype across world populations
2016352 citationsAndrea Gaedigk, Katrin Sangkuhl et al.profile →
Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
2014345 citationsHenry M. Dunnenberger, Kelly E. Caudle et al.profile →
ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs
2020208 citationsLi Gong, Kelly E. Caudle et al.Clinical Pharmacology & Therapeuticsprofile →
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing
2020194 citationsJulia M. Barbarino, Zeruesenay Desta et al.Clinical Pharmacology & Therapeuticsprofile →
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants
2023181 citationsKatrin Sangkuhl, J. Steven Leeder et al.Clinical Pharmacology & Therapeuticsprofile →
PharmVar GeneFocus: CYP2B6
2021178 citationsZeruesenay Desta, Li Gong et al.Clinical Pharmacology & Therapeuticsprofile →
ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)
This map shows the geographic impact of Teri E. Klein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teri E. Klein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teri E. Klein more than expected).
This network shows the impact of papers produced by Teri E. Klein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teri E. Klein. The network helps show where Teri E. Klein may publish in the future.
Co-authorship network of co-authors of Teri E. Klein
This figure shows the co-authorship network connecting the top 25 collaborators of Teri E. Klein.
A scholar is included among the top collaborators of Teri E. Klein based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Teri E. Klein. Teri E. Klein is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Amstutz, Ursula, Linda M. Henricks, Steven M. Offer, et al.. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology & Therapeutics. 103(2). 210–216.406 indexed citations breakdown →
11.
Bishop, Jeffrey R., Katrin Sangkuhl, Daniel J. Müller, et al.. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. PMC.51 indexed citations
Caudle, Kelly E., Allan E. Rettie, Michelle Whirl‐Carrillo, et al.. (2014). Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.. The Medicine Forum. 96(5). 542.6 indexed citations
14.
Altman, Russ B., et al.. (2014). Pacific Symposium on Biocomputing 2016.44 indexed citations
15.
Mi, Huaiyu, Paul D. Thomas, Huijun Z. Ring, et al.. (2010). PharmGKB summary. Pharmacogenetics and Genomics. 21(6). 350–356.10 indexed citations
16.
Yang, Jun J., Erin G. Schuetz, Mark J. Ratain, et al.. (2009). Etoposide pathway. Pharmacogenetics and Genomics. 19(7). 552–553.40 indexed citations
17.
Litonjua, Augusto A., Li Gong, Qing Duan, et al.. (2009). Very important pharmacogene summary ADRB2. Pharmacogenetics and Genomics. 20(1). 64–69.70 indexed citations
Hunter, Lawrence & Teri E. Klein. (1995). Pacific Symposium on Biocomputing '96 : Hawaii, USA, 3-6 January, 1996. WORLD SCIENTIFIC eBooks.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.